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trait (minor), 100% for beta-thalassemia major and variable 
between 50-80% for beta-thalassemia intermedia. Although in 
beta-thalassemia trait, the beta-globin chain production deficit 
is 50%, the Hb is normal or mildly reduced. The excess alpha 
globin chains are removed by proteolysis and compensation is 
seen by increased erythropoesis.
Anaemia is the most common condition seen in clinical practice 
in all age groups. Red blood cell production requires an adequate 
supply of iron, folate, vitamin B12 and pyridoxine. The cause 
of the anaemia encompasses nutritional deficiencies including 
the underlying disease process. Anaemia of chronic disease is 
commonly seen in hospital patients. In surgical patients and 
those with disease processes where blood loss is featured, iron 
deficiency anemia is seen. In oncology patients, including 
those with haematological diseases, marrow infiltration alters 
hemopoiesis and chemotherapy results in suppression. Nutrition 
in addition may be compromised in oncology patients4. In 
populations where thalassemia is prevalent, iron deficient red 
blood cell indices may be confused with thalassemia indices. 
Classical beta-thalassemia trait has hypochromic microcytic 
red cell indices and a raised HbA2 with values 4% and above 
when measured by high performance liquid chromatography 
(HPLC)5-8. In beta-thalassemia intermedia and major the red 
cell indices are also hypochromic and microcytic. However 
the peripheral blood film has profound red cell morphological 
changes. HbF (a2γ2) is raised and no HbA (a2β2) is synthesized 
in beta-thalassemia major. In beta-thalassemia intermedia 
and major, the serum ferritin is raised or may be normal in 
the presence of iron chelation therapy9. In classical beta-
thalassemia carriers, the serum ferritin levels are normal10. 
However, carriers can show functional iron deficiency11. In 
pregnancy iron supplementation may be required in beta-
thalassemia carriers.
GENETIC MODIFIERS
The major genetic modifiers of β-thalassemia are the genotypes 
of the β- and a- globin and expression of γ-globin.
The spectrum of beta-thalassemia alleles has been determined 
in a wide variety of population groups. At present, more than 
200 different beta-thalassemia mutations have been described. 
List of mutations causing β-thalassemia is available at the globin 
gene server (http://globin.cse.psu.edu). The large majority of 
mutations causing β-thalassemia are primarily point mutations 
and others include deletions or addition of nucleotides that 
involve the beta-globin gene complex. Expression of the beta-
The haemoglobinopathies and thalassemias represent the 
most common inherited monogenic disorders in the world1. 
Beta-thalassaemia major is an ongoing public health problem 
in Malaysia2. Prior to 2004, the country had no national policy 
for screening and registry for thalassemia. In the absence of 
a national audit, the true figure of the extent of thalassemia 
in the Malaysian population was largely presumptive from 
micro-mapping studies from various research workers in the 
country. The estimated carrier rate for beta-thalassemia in 
Malaysia is 3.5-4%. There were 4768 transfusion dependent 
thalassemia major patients as of May 2010 (Data from National 
Thalassemia Registry).
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PATHOPHYSIOLOGY OF ANEMIA IN BETA-THALASSEMIA 
Thalassemia is a disorder of haemoglobin synthesis which 
is characterized by the absence or reduced synthesis of 
globin chains, a,β,δ,γ,ζ and ε of human haemoglobin (Hb). 
The two main types of thalassemia are a and β-thalassemia. 
Phenotypically there two forms of β-thalassemia: β0 – no 
β globin chain synthesis, and β+ - with some β globin chain 
synthesis. Clinically, thalassemia presents as beta-thalassemia 
trait (minor) (β+ or β0), intermedia (β+/β+; β+/β0) or major (β0/
β0). Beta-thalassemia trait (minor) is usually asymptomatic 
and is associated with the inheritance of a single gene defect. 
Beta-thalassemia major results in severe transfusion dependent 
anemia and is caused by the inheritance of two beta-globin 
gene mutations either in a compound heterozygous or 
homozygous state. Beta-thalassemia intermedia is of moderate 
severity and the majority of affected individuals do not require 
regular blood transfusions3.
In beta-thalassemia the synthesis of the alpha globin chains 
continue despite the absence or reduced synthesis of the beta-
globin chains of human haemoglobin. This imbalance of the 
globin chains is the cause of the anemia in thalassemia. The 
excess alpha globin chains precipitate in the developing red 
blood cells in bone marrow and in the peripheral blood resulting 
in their damage and reduced red cell survival. Inclusion body 
formation and oxidative damages to developing red blood cells 
in the bone marrow leads to ineffective erythropoiesis which 
is the hallmark of thalassemia. Red blood cells formed that 
are able to make their way into the peripheral blood also get 
destroyed in a similar way resulting in peripheral hemolysis. 
The beta-globin chain deficit is 50% for beta-thalassemia 
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globin genes may be affected by mutations in the regulatory 
regions upstream of the beta-globin gene complex. Population 
studies demonstrated that approximately 25 mutations 
represent the vast majority of the β-thalassemia alleles in all 
populations at risk. A small number of ethnic/population 
group-specific alleles account for about 70-90% of the beta-
thalassemia genes while a larger number of rarer alleles have 
been observed in each ethnic group that account for the 
remaining genes12-13.
The total population in Malaysia is estimated as 28 million. 
Malaysia is multiracial with different religions and cultural 
beliefs. The three main races are the Malays (65%), Chinese 
(26%) and Indians (8%). In addition there are Ceylonese, 
Indonesians, Pakistani, Myanmar, Thais and Europeans. 
Indigenous people are present in Peninsular Malaysia (Orang 
Asli) and in East Malaysia (Sarawak and Sabah). Each ethnic 
group has its characteristic set of beta-thalassemia mutations. 
The spectrum of beta-thalassemia mutations in Malaysia 
have been systematically delineated since 1984. Three 
common β-globin mutations seen in the Malays, HbE [CD 
26 (CAG→AAG)], IVS 1-5 (G→C) and IVS1-1 (G→T) were 
responsible for about 73.1% of β-thalassemia. HbE and IVS1-5 
(G→C) both have β+-thalassemia phenotype. There are five 
common β-globin mutations in the Chinese-Malaysians: CD 
41/42 (-TCTT), IVS2-654 (C→T), -28 (A→G), CD 17 (A→T) and 
CD71/72 (+A) and these account for about 90% of β-thalassemia. 
All have β0-thalassemia phenotype except IVS2-654(C→T) 
and -28 (A→G) which have β+-thalassemia phenotype. In the 
Kadazan-Dusun of Sabah the most common mutation found in 
over 90% of transfusion dependent thalassemia patients is the 
45 kb Filipino deletion. This latter mutation has β0-thalassemia 
phenotype14-30.
Alpha globin chains in beta-thalassemia can combine with 
gamma and delta globin chains to form HbF (a2γ2) and HbA2 (a2δ2) 
respectively. However this expression is affected by factors that 
modulate alpha globin chain excess and its stability. Genetic 
factors include the specific beta-thalassemia mutation, alpha 
globin gene dosage, gamma chain expression and membrane 
disorders. The primary beta globin gene mutation expression 
as β+ is β0 is a critical factor. Mild mutations have less reduction 
in beta-globin chain production resulting in some HbA (a2β2) 
formation whereas in beta-thalassemia major (β0/β0) there is no 
beta globin chain formed at all and the affects of deleterious 
access of alpha globin chains are clearly seen. Compound 
βE/β0- thalassemia is the most common form of severe beta-
thalassemia in southeast Asian countries. The βE-globin allele 
bears a point mutation that causes alternative splicing. The 
abnormally spliced form is non-coding producing no βE. The 
correctly spliced messenger RNA expresses a mutated βE-globin 
with instability. Interaction with a non-functional β0 allele 
results in profound decrease in β-globin chain synthesis. About 
50% of βE/β0- thalassemia patients are transfusion dependent.
A normal person has four alpha globin genes producing 
alpha globin chains. Thus, alpha thalassemia ameliorates 
beta-thalassemia by reducing the excess alpha globin chains 
whereas presence of more than 4 functional alpha globin 
genes aggravates the condition. This latter status results in the 
production of more alpha globin chains contributing to excess 
of alpha globin chains in beta-thalassemia. The concurrent 
inheritance of a-thalassemia 1 (--SEA)(a0-thalassemia) with beta-
thalassemia was seen in 3.5%31-33. Concurrent inheritance of 
deletional a-thalassaemia in Malays with HbE trait was seen 
in 11.1% where the most prevalent interaction was with a+-
thalassemia (a-3.7). Only 2.2% had the a0-thalassemia molecular 
defect34-35.
The stability of unpaired alpha globin chains is modulated by 
alpha-haemoglobinstabilizing-protein (AHSP). AHSP has been 
described to play an important role in erythropoiesis. It is 
involved in folding of the alpha-globin chains for beta-globin 
association, heme binding, transfer for beta-globin association 
and stabilization of alpha-globin chains. Mice lacking AHSP 
have abnormal red cell production and lifespan. AHSP is a 
specific molecular chaperone that binds alpha-globin chain of 
haemoglobin and prevents alpha globin chain precipitation36-
37. AHSP inhibits reactive oxygen species (ROS) production 
from alpha-globin chain excess38.
Reduced AHSP can mean reduced protection from stressors such 
as fever, oxidizing conditions and presence of toxins. In mice, 
the phenotype of beta-thalassemia intermedia is exacerbated 
by concomitant loss of AHSP39. However studies in humans 
with thalassemia produced variable data on AHSP as a modifier 
of beta-thalassemia phenotype suggesting that there may be 
population variability of AHSP expression. GATA-1 and Oct-1 
are regulatory elements required for the expression of the 
human AHSP gene. The AHSP promoter region is an excellent 
candidate region for mutations associated with decreased or 
increase AHSP gene expression40. AHSP expression in HbE-
beta-thalassemia patients varied up to 1.52 –log differences 
in a cohort of patients studied in West Malaysia41. Studies in 
patients with mild, moderate and severe HbE beta-thalassemia 
in Thailand suggested that AHSP is not a disease modifier in 
this form of thalassemia42.
Human Hb production is characterized by two major ` switches’: 
production of embryonic Hb (Hb Gower 1 (a2ε2); Hb Gower 2 
(ζ2ε2) and Hb Portland (ζ2γ2) and swithches after 2 months of 
gestation to production of two types of fetal Hb (a2
Gγ2 and a2 
Aγ2) and just before birth to adult Hb A (a2β2). At 6 months 
after birth, HbF comprises less than 5% of total Hb and reaches 
adult level at 2 years of age43. Clinically severe forms of beta-
thalassemia become apparent on completion of the switch 
from fetal to adult Hb. The majority of beta-thalassemia major 
patients will present in the first year of life and the rest in the 
second. There is considerable variation in the amount of HbF 
levels in normal adults. Factors known to influence HbF levels 
are age, sex, inheritance of β thalassemia and genetic factors 
such as DNA sequence variations within the β globin gene 
cluster as well as genes unlinked to the β globin gene cluster44. 
Increased HbF levels or F-cell (HbF containing erythrocyte) 
numbers can ameliorate the disease severity of β-thalassemia 
major.
Increased HbF levels may occur as a direct or indirect effect of 
genetic disorders. Inherited disorders primarily associated with 
increased HbF levels due directly to increased production fall 
into two groups – hereditary persistence of fetal hemoglobin 
(HPFH) and δβ-thalassemia. Genetic disorders indirectly 
associated with increased HbF levels are the beta-thalassemias. 
β-thalassemia trait usually have normal or slightly increased HbF 
levels. The range of HbF levels in homozygous β-thalassemia 
range from 10% in mild alleles (β+) and to about 100% in those 
with β0 alleles. A sequence variation (C→T) at position -158 
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upstream of the Gγ globin gene has been shown to increase HbF 
levels in both normal individuals and in patients with beta-
thalassemia 45-46. Studies in Thailand indicate that the HbF level 
increase is more significant when this gene polymorphism is 
inherited in a homozygous state. In Malays, heterozygosity of 
the Xmn 1 site (+/-) was most common and seen in 63.3% of 
patients with beta-thalassemia. Homozygosity for the Xmn 1 
site (+/+) was absent in the Chinese-Malaysians but identified 
in 8.2% of the Malay patients. Homozygosity for the Xmn 1 
(-/-) was seen in 89.7% of Chinese-Malaysian patients with 
beta-thalassemia major47.
Recent genome-wide association studies reported that single 
nucleotide polymorphisms (SNPs) in the BCLL11A gene on 
chromosome 2p16.1 were correlated with F-cells among 
healthy Europeans, and HbF among Sardinians, Chinese and 
Thais with beta-thalassemia. BCL11A is a major Hb quantitative 
trait locus in populations with β-thalassemia. Data suggest that 
functional motifs responsible for modulating F-cells and HbF 
levels reside with a 3 kb region of the BCL11A gene48.
Hereditary ovalostomatocytosis is a common inherited 
membrane disorder present in 5.1% of Malays49. Ektacytometric 
studies of peripheral blood show membranes of red blood cells 
in hereditary ovalostomatocytosis are markedly rigid50-51. The 
clinical effects of the genes of beta-thalassemia and hereditary 
ovalocytosis are summated in an aggravation of haemolysis52.
TREATMENT OPTIONS AND EMERGING THERAPIES
Beta-thalassemia carriers are asymptomatic and do not require 
blood transfusions. However functional iron deficiency may 
occur in this group and treatment by hematinics. In the majority 
of patients with beta-thalassemia intermedia blood transfusion 
may be required in fulminant infections, during pregnancy and 
when drugs with oxidant properties are administered. In severe 
beta-thalassemia (thalassemia major), unbalanced globin chain 
synthesis produces extensive destruction of immature red cells 
in the bone marrow (ineffective erythropoiesis) and mature 
red blood cells in the peripheral blood (peripheral hemolysis) 
resulting in anemia. Anemia provokes compensatory 
hyperplasia of the erythroid marrow. Ferrokinetic studies 
indicate erythroid proliferation may exceed about 10-20 times 
basal level. Additional deleterious effects caused by the erythroid 
bone marrow expansion include increased iron absorption, 
extramedullary hemopoietic masses and hypercatabolic state. 
Studies indicate that a transfusion program of regular monthly 
blood transfusions of packed red blood cells keeping a baseline 
Hb of 9-10 g/dl suppresses erythropoiesis53-54.
In Malaysia, the conventional mode of therapy in beta-
thalassemia major patients is regular monthly transfusions for 
life. Patients require iron chelation to remove the excess iron 
that accumulates in the body from both the blood transfusions 
and from increased iron absorption from the gastrointestinal 
tract55.
Allogeneic hemopoietic stem cell (HSC) transplantation is 
currently the only treatment with curative potential for severe 
beta-thalassemia. Stem cells are sourced from umbilical cord 
blood, peripheral blood and bone marrow of human leukocyte 
antigen (HLA) matched donors56-57. Facilities are available in 
four centres in Malaysia for HSC transplantation58-59. A total of 
144 transplants for thalassemia have been recorded from 1997 
to 2008. [The National Transplant Registry; University Malaya 
Medical Centre contributed 98 cases: Data from Professor 
Chan LL (personal communication)]. HSC source consisted 
of compatible bone marrow and umbilical cord. The overall 
survival rate is 82%. The cure rate does not differ by more than 
5% from survival rate.
The only established curative therapy for beta-thalassemia 
major is allogeneic stem cell transplantation from a matched 
related donor. However, at least 70% of these patients lack 
such a donor. An emerging treatment is gene therapy for 
gene transfer using lentoviral vectors. Experiments in animal 
models, mice with beta-globin mutations have demonstrated 
the efficacy of globin gene transfer using lentoviral vectors. 
The first human thalassemia patient treated with gene therapy 
using a lentoviral vector in 2007 was reported as transfusion 
independent in 201060. Gene transfer of the hepcidin gene 
(HAMP) to reduce intestinal iron absorption and restoration of 
the balanced a/β globin gene expression in β654-thalassemia 
mice using combined RNA and antisense RNA approach have 
been reported. In β-thalassemia, given the excess of a-globin 
leads to widespread detrimental effects, it was found that using 
the RNAi pathway to mediate reduction in a-globin expression 
has potential as a therapeutic strategy61-62.
Increased HbF synthesis ameliorates beta-thalasemia. 
Reactivation of γ-chain synthesis is a tangible approach 
showing beneficial effects. In β-thalassemia the additional γ 
chains bind to the a-chains remaining in excess because of 
absence of their normal partners the β-chains: This result in 
ameliorating the deleterious effects of intracellular precipitation 
of excess of a-chains and production of some functional 
HbF in the developing red cell precursors occurs: Ineffective 
erythropoiesis is reduced and the red cells survive longer in 
the circulation63. Coinheritance of hereditary persistence fetal 
hemoglobin (HPFH) reduces clinical severity. Pharmacological 
manipulation has been approached to increase Hb F production. 
5-azacytidine, sodium 4 phenylbutyrate and hydroxyurea are 
compounds able to do this. However 5-azacytidine is potentially 
carcinogenic and restricted to end stage β-thalassemia patients 
where transfusion therapy is not possible due to development 
of antierythrocyte antibodies or intractable iron overload64. A 
number of clinical trials have used hydroxyurea either alone 
or with erythropoietin to maintain transfusion independence 
or reduce transfusions. Studies with beta-thalassemia with 
hydroxyurea indicate however the increase in HbF levels may 
not be adequate to maintain transfusion independence 65-66.
SUMMARY
In Malaysia, best possible care is provided to beta-thalassemia 
major patients by conventional treatment of optimal regular 
monthly transfusion and iron chelation. Cure through 
hemopoietic stem cell transplantation being offered to a 
limited few where a HLA matched compatible sibling donor 
is available. Improved understanding of the pathophysiology 
of beta-thalassemia in the last two decades indicates that 
gene therapy provides the potential for molecular therapies. 
Molecular analysis of patients with thalassemia to identify 
gene modifiers will improve genetic counselling and clinical 
management in Malaysia.
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